Article Versions Notes

Lamoine S, Cumenal M, Barriere DA, Pereira V, Fereyrolles M, Prival L, Barbier J, Boudieu L, Brasset E, Bertin B, et al. The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice. International Journal of Molecular Sciences. 2022; 23(1):98. https://doi.org/10.3390/ijms23010098

Lamoine, Sylvain, Mélissa Cumenal, David A. Barriere, Vanessa Pereira, Mathilde Fereyrolles, Laëtitia Prival, Julie Barbier, Ludivine Boudieu, Emilie Brasset, Benjamin Bertin, and et al. 2022. "The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice" International Journal of Molecular Sciences 23, no. 1: 98. https://doi.org/10.3390/ijms23010098

Lamoine, S., Cumenal, M., Barriere, D. A., Pereira, V., Fereyrolles, M., Prival, L., Barbier, J., Boudieu, L., Brasset, E., Bertin, B., Renaud, Y., Miot-Noirault, E., Civiale, M. -A., Balayssac, D., Aissouni, Y., Eschalier, A., & Busserolles, J. (2022). The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice. International Journal of Molecular Sciences, 23(1), 98. https://doi.org/10.3390/ijms23010098